PCI Biotech - Fundamentale forhold (PCIB)

Bonusfrelst · oktober 25, 2021, 9:28am

Så endepunktene er møtt på bla OS? Hvorfor er ikke denne utfordreren blitt nevnt av PCIB selv tidligere? Er vel bare NuCana

laplagam · oktober 27, 2021, 3:16pm

2 posts were merged into an existing topic: PCI Biotech - Småprat 4 (PCIB) 2

Tekspert · november 1, 2021, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@lenny (307 likes)

@Jubel (295 likes)

@abacus (191 likes)

Resten av topp 10:

@bamse (174 likes)
@Investor (143 likes)
@Logdec (128 likes)
@Oxion (109 likes)
@olafalo (108 likes)
@neuro (103 likes)
@anon6994212 (95 likes)

Gratulerer!

polygon · november 2, 2021, 9:16am

“mFOLFIRINOX triplet chemotherapy did not meet the primary study end point. CISGEM doublet chemotherapy remains the first-line standard in advanced BTC”

abacus · november 2, 2021, 10:00am

Det må nok lokal behandling til for at gallegangen ikke skal tettes til

TekBot · november 8, 2021, 10:15am

PCI Biotech: Presentation of fimaChem for bile duct cancer at IPA masterclass series

Oslo (Norway), 8 November 2021 - PCI Biotech (OSE: PCIB), a cancer focused
biopharmaceutical company, today announced that the coordinating principal
investigator for the RELEASE trial, Prof. Dr. Jörg Trojan, Head of
…

Vis børsmeldingen

Gastrointestinal Oncology Unit, Goethe University Hospital, Frankfurt, Germany
will present results from the fimaChem Phase I study in bile duct cancer and the
design and status of the ongoing pivotal RELEASE study at the online event
‘Light-responsive platforms for controlled drug delivery’ hosted by IPA
(International Photodynamic Association).

The online event is scheduled for 15:30-18:00 CET today and the presentation by
Prof. Trojan is named ‘PCI of gemcitabine in locally advanced inoperable
cholangiocarcinoma - a new technique with promising clinical activity’. Please
find the presentation enclosed.

The event also includes a presentation by Dr Pål K. Selbo, Oslo University
Hospital, showcasing preclinical research from the Oslo University Hospital
applying the PCI technology for delivery of cancer immunotherapeutics.

Contact information:
Per Walday, CEO
[email protected] (mailto:[email protected])
Mobile: +47 917 93 429

About PCI Biotech
PCI Biotech is a biopharmaceutical late-stage clinical development company
focusing on development and commercialisation of novel therapies for the
treatment of cancer through its innovative photochemical internalisation (PCI)
technology platform. PCI is applied to three distinct anticancer paradigms:
fimaChem (enhancement of chemotherapeutics for localised treatment of cancer),
fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc
(nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used
to unlock the true potential of a wide array of therapeutic modalities. The
company’s lead programme fimaChem consists of a pivotal study in bile duct
cancer, an orphan indication with a high unmet need and without approved
products. fimaVacc applies a unique mode of action to enhance the essential
cytotoxic effect of therapeutic cancer vaccines, which works in synergy with
several other state-of-the-art vaccination technologies. fimaNAc utilises the
endosomal release to provide intracellular delivery of nucleic acids, such as
mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks
facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com
(http://www.pcibiotech.com)

Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

Kilde

laplagam · november 8, 2021, 10:20am

Nedenfor er link til presentasjonen

https://ml-eu.globenewswire.com/Resource/Download/8ab949e8-1af6-48c2-aefa-51501d1ee4c1

TekBot · november 9, 2021, 8:31am

PCI Biotech to present at the 9th International mRNA Health Conference

Oslo (Norway), 9 November 2021 - PCI Biotech (OSE: PCIB), a clinical-stage
biopharma company developing innovative therapeutics that address significant
unmet medical needs in cancer today announced that it will present a poster at
…

Vis børsmeldingen

the 9(th) International mRNA Health Conference, a combined on-site and virtual
event taking place November 9-10, 2021 in Berlin, Germany.

Today at 16:45 - 18:30 (CET), Dr. Anders Høgset, CSO, will on-site present a
poster named ‘Photochemical internalisation (PCI) - enhanced and site-directed
mRNA delivery by light-induced endosomal release’ giving an overview of PCI
Biotech’s proprietary platform technology for use in the exciting field of mRNA-
based therapies. Please find the poster enclosed.

Contact information:
Per Walday, CEO
[email protected] (mailto:pw@)
Mobile: +47 917 93 429

About The International mRNA Health Conference
The International mRNA Health Conference is the premier meeting destination for
industry and academic professionals to explore the rapidly advancing science and
business of mRNA medicines. The conference provides participants with a platform
for networking with experts, giving them an opportunity to learn more about
developments in mRNA technology and to see scientific presentations by some of
the most esteemed experts in the field. The event brings together over 650
attendees from leading pharma and biotech companies as well as academic
institutions.

About PCI Biotech
PCI Biotech is a biopharmaceutical late-stage clinical development company
focusing on development and commercialisation of novel therapies for the
treatment of cancer through its innovative photochemical internalisation (PCI)
technology platform. PCI is applied to three distinct anticancer paradigms:
fimaChem (enhancement of chemotherapeutics for localised treatment of cancer),
fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc
(nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used
to unlock the true potential of a wide array of therapeutic modalities. The
company’s lead programme fimaChem consists of a pivotal study in bile duct
cancer, an orphan indication with a high unmet need and without approved
products. fimaVacc applies a unique mode of action to enhance the essential
cytotoxic effect of therapeutic cancer vaccines, which works in synergy with
several other state-of-the-art vaccination technologies. fimaNAc utilises the
endosomal release to provide intracellular delivery of nucleic acids, such as
mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks
facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com
(http://www.pcibiotech.com)

Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

Kilde

TekBot · november 9, 2021, 11:50am

PCI Biotech: Invitation to Q3 2021 result presentation

Oslo, Norway, 9 November 2021 - PCI Biotech (OSE: PCIB) invites to a
presentation of the company’s Q3 2021 results on Wednesday 17 November 2021 at
Oslo Cancer Cluster Innovation Park.
…

Vis børsmeldingen

Time: Wednesday 17 November, 08:30am - 09:30am CET (local time).
Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster
Innovation Park, Ullernchausséen 64, Oslo.

The presentation will be held in English and if you wish to attend the
presentation in person, please confirm with an e-mail to [email protected].

The presentation will also be a live webcast and can be accessed through
www.pcibiotech.com. There will be a Q&A session at the end of the presentation
and it will be possible to post written questions through the webcast console or
through a teleconference facilitated for investors intending to ask questions
verbally during the Q&A session.

PCI Biotech’s Q3 2021 interim report will be released on 17 November 2021 at
07.00 CET. The interim report and presentation will be made available on
www.newsweb.no and on the company’s webpage, www.pcibiotech.com.

For further information, please contact:
Ronny Skuggedal, CFO
Email: [email protected]
Mobile: +47 9400 5757

About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company
focusing on development and commercialisation of novel therapies for the
treatment of cancer through its innovative photochemical internalisation (PCI)
technology platform. PCI is applied to three distinct anticancer paradigms:
fimaChem (enhancement of chemotherapeutics for localised treatment of cancer),
fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc
(nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used
to unlock the true potential of a wide array of therapeutic modalities. The
company’s lead programme fimaChem consists of a pivotal study in bile duct
cancer, an orphan indication with a high unmet need and without approved
products. fimaVacc applies a unique mode of action to enhance the essential
cytotoxic effect of therapeutic cancer vaccines, which works in synergy with
several other state-of-the-art vaccination technologies. fimaNAc utilises the
endosomal release to provide intracellular delivery of nucleic acids, such as
mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks
facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com
(http://www.pcibiotech.com)
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379
Oslo

Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

Kilde

Snoeffelen · november 9, 2021, 11:56am

Ser ut som at man på første gang på veldig lenge får anledning til å møte ledelsen i PCI Biotech face-to-face.

TekBot · november 17, 2021, 6:01am

PCI Biotech Q3 2021 interim results

Oslo (Norway), 17 November 2021 - PCI Biotech (OSE: PCIB), a cancer focused
biopharmaceutical company, today announces its interim Q3 2021 results. Please
find enclosed the report and presentation.
…

Vis børsmeldingen

Highlights

fimaChem
*Enrolment of patients into the RELASE study is still challenging and
fluctuating - Covid-19 has a continued negative impact on the study and with
August being a low recruitment month due to the holiday season, only five
patients were enrolled in Q3

*Three patients were enrolled into the RELEASE study in October and the company
continues to have a strong focus on recruitment, with the emphasis on regular
trial management, including overall performance evaluation and site replacement

*Thirty patients have per end of October been included in the RELEASE study and
the expected timeline for interim analysis remains 2H 2023

*Proactively pursuing strategies to address recruitment and retention, including
interactions with FDA and EMA about an alternative study design

fimaVacc
*The programme is progressing towards initiation of a Phase II clinical proof-
of-concept study, with product definition and study design clarified following
comprehensive consultations with international experts

fimaNAc
*Development plan initiated based on strategic research and collaborations,
targeting applications suited to the specific strengths of the PCI technology

Corporate
*Significantly strengthening the organisation with three highly skilled
individuals; an experienced operational leader for RELEASE, and two key
employees within clinical science and business development focusing on fimaVacc
and fimaNAc

Per Walday, CEO of PCI Biotech, comments: “The strengthening of the organisation
with three key employees has contributed positively to the progress in all
development areas, but the RELEASE study is unfortunately still affected by the
Covid-19 pandemic. Scheduling of local administration of light to the bile duct
by endoscopy remains challenging in the RELEASE study, as clinical trial sites
continue to deal with a backlog of patients. The situation is expected to
improve as the vaccination rates increase going forward. We are fully focused on
optimal study performance and progress, with attention to site performance and
proactive management of study specific risks. We are also pursuing strategic
options to address retention and recruitment, including ongoing interactions
with regulatory authorities regarding a well-prepared and rational study design
change utilising external control data in RELEASE. The initial responses from
regulatory authorities do however suggest significant challenges for using this
approach in a pivotal trial of a first line treatment. We are pleased to provide
more granularity on the next steps for fimaVacc, as product definition and study
approach has been further clarified following comprehensive interactions with
KOLs. We look forward to bringing this exciting programme with encouraging early
clinical immune response results to proof-of-concept in a combination treatment
setting with immunomodulation in solid tumours. A stronger strategic focus has
been applied to the fimaNAc programme with emphasis on specific applications
lending themselves to the strength of the PCI technology, and we continue to
pursue new and value-adding collaborative opportunities.”

The presentation will be held in English today, Wednesday 17 November 2021, at
08.30am CET (local time). The presentation can be followed as a live webcast,
access through link
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20211117_3 or the
company’s website under “Investors - Reports and presentations - Webcasts”.

Q&A session
There will be a Q&A session at the end of the presentation and it will be
possible to post written questions through the webcast console. The presentation
will also be presented through a teleconference, mainly facilitated for
investors intending to ask questions verbally during the Q&A session.

Dial-in details for teleconference, mainly facilitated for verbal questions
during Q&A session:
If you plan to use this facility, please join the event 5-10 minutes prior to
the scheduled start time using the dial-in numbers below. A line mediator will
provide information on how to ask questions.

Norway +47 2350 2007 / Sweden +46 (0)8 5033 6574 / Denmark +45 35 15 80 49 /
United Kingdom +44 (0)330 336 9125 / United States +1 929 477 0324. If your
country is not listed, we recommend that you use the dial-in details for UK.

When prompted, provide the confirmation code or event title.

Confirmation Code: 7356590
Event title: PCI Biotech

The interim report and the presentation will also be available on www.newsweb.no
and on the company’s webpage, www.pcibiotech.com from 07:00am CET on 17 November
2021.

For further information, please contact:
Ronny Skuggedal, CFO
Email: [email protected]
Mobile: +47 9400 5757

About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company
focusing on development and commercialisation of novel therapies for the
treatment of cancer through its innovative photochemical internalisation (PCI)
technology platform. PCI is applied to three distinct anticancer paradigms:
fimaChem (enhancement of chemotherapeutics for localised treatment of cancer),
fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc
(nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used
to unlock the true potential of a wide array of therapeutic modalities. The
company’s lead programme fimaChem consists of a pivotal study in bile duct
cancer, an orphan indication with a high unmet need and without approved
products. fimaVacc applies a unique mode of action to enhance the essential
cytotoxic effect of therapeutic cancer vaccines, which works in synergy with
several other state-of-the-art vaccination technologies. fimaNAc utilises the
endosomal release to provide intracellular delivery of nucleic acids, such as
mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks
facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com
(http://www.pcibiotech.com)
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379
Oslo

Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

Kilde

StockDZ · november 24, 2021, 2:22pm

hi

Now you can watch IPA master classes series regarding PCI for which the company sent out a press release few weeks ago. both Pål Selbo and Prof Jorg Trojan are presenters

click on first video. it combines three presentations, follow the timelines:

31:14 … PCI and Light-Controlled Delivery of Cancer Immunotherapeutics - Pål Kristian Selbo, PhD
01:00:20 … PCI of Gemcitabine in Locally Advanced Inoperable Cholangiocarcinoma - A new technique with promising clinical activity - Jorg Trojan, PhD

IPA Video Podcasts — International Photodynamic Association (IPA)

ufo · november 25, 2021, 7:16am

Dette innlegget ble rapportert og er midlertidig skjult.

ufo · november 24, 2021, 11:58pm

Er det bare jeg eller er det slik at der er problemer med å finne en småprat-tråd for PCIB?
Kunne noen opprette en slik side?
Slik det er i dag så blir tråden for fundamentale forhold “misbrukt” , ikke?

startw1n · november 25, 2021, 5:46am

Her er den!

TekBot · november 29, 2021, 10:07am

PCI Biotech to present at ABGSC Nordic Rare Disease Seminar

Oslo (Norway), 29 November 2021 - PCI Biotech (OSE: PCIB), a clinical-stage
biopharma company developing innovative therapeutics that address significant
unmet medical needs in cancer today announced that it will present at the Nordic
…

Vis børsmeldingen

Rare Disease Seminar, a Stockholm based online event hosted by ABG Sundal
Collier.

Today at 11:45 (CET), Dr. Per Walday, CEO, will give an online presentation
focusing on the pivotal RELEASE trial with registration intent for the rare
disease bile duct cancer, an orphan disease with a high unmet medical need. The
presentation will be made available on PCI Biotech’s website, www.pcibiotech.com
under Investors/Reports and presentations/Other presentations.

Contact information:
Per Walday, CEO
[email protected]
Mobile: +47 917 93 429

About PCI Biotech
PCI Biotech is a biopharmaceutical late-stage clinical development company
focusing on development and commercialisation of novel therapies for the
treatment of cancer through its innovative photochemical internalisation (PCI)
technology platform. PCI is applied to three distinct anticancer paradigms:
fimaChem (enhancement of chemotherapeutics for localised treatment of cancer),
fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc
(nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used
to unlock the true potential of a wide array of therapeutic modalities. The
company’s lead programme fimaChem consists of a pivotal study in bile duct
cancer, an orphan indication with a high unmet need and without approved
products. fimaVacc applies a unique mode of action to enhance the essential
cytotoxic effect of therapeutic cancer vaccines, which works in synergy with
several other state-of-the-art vaccination technologies. fimaNAc utilises the
endosomal release to provide intracellular delivery of nucleic acids, such as
mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks
facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com
(http://www.pcibiotech.com)

Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

Kilde

Jubel · november 30, 2021, 8:13am

PCI BIOTECH AND IMMUNICUM ANNOUNCE AN EXTENSION TO THEIR RESEARCH COLLABORATION TO EXPLORE NOVEL CANCER VACCINATION TREATMENTS

Oslo, Norway, November 30, 2021 - PCI Biotech Holding ASA (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology via Photochemical Internalisation and Immunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, announced today an extension of their current collaboration.

The companies jointly research the possibility to overcome current hurdles in cancer immunotherapy by introducing tumor independent immune targets into the tumor microenvironment, in combination with vaccination or adoptive immunotherapies. The so-called Tumor Independent Antigen concept, which has been invented by Immunicum, could benefit from PCI Biotech’s antigen delivery technologies based on Photochemical Internalisation. Following the encouraging results of the first set of in vitro experiments, during which the delivery protocol of the combination treatment has been optimized, the companies have decided to move ahead to evaluate the novel therapeutic concept in animal models. While the first experiments were conducted by Immunicum, this further in vivo evaluation will be carried out by PCI Biotech.

Commenting on the announcement PCI Biotech’s CEO, Per Walday said: “The results of the initial collaborative experiments are encouraging, supporting the immune response enhancing capability of the fimaVacc platform technology. We are committed to this collaboration and are looking forward to the next series of experiments in animal models, which are aimed to generate data that could pave the way to a potential joint development program.”

Erik Manting, CEO of Immunicum added: “At Immunicum, we are continuously studying novel immunotherapy concepts aimed to address hard-to-treat established tumors and to overcome the limitations of currently available cancer therapies. In this collaboration, we are combining our know-how and technology basis with that of PCI Biotech to design potential novel therapeutic concepts and we look forward to advancing the collaboration through in vivo studies as an important next step.”

Tekspert · desember 1, 2021, 10:00am